Biotechnology industry in Italy is a highly innovative and fast-growing sector dedicated to research. At the end of 2019, there are 696 biotech companies active in Italy. [1]
The turnover exceeds 12 billion euros, the number of employees exceeds 13,000 units. Between 2017 and 2019, over 50 new innovative start-ups active in biotechnology were registered. [2]
In the laboratories of the IRBM Science Park a team of Italian and American researchers has developed the Chad3Ebola-Zaire anti-ebola vaccine, a monovalent adenovirus capable of neutralizing the «Zaire» strain of the virus, conceived and produced by OKAIROS, a biotech company founded by Prof. Riccardo Cortese, with whom IRBM set up the Advent equal joint venture.
This section is empty. You can help by
adding to it. (January 2024) |
The research intensity of the biotech sector is significantly higher than that found for the Italian industry as a whole. [9]
Biotechnology industry in Italy is a highly innovative and fast-growing sector dedicated to research. At the end of 2019, there are 696 biotech companies active in Italy. [1]
The turnover exceeds 12 billion euros, the number of employees exceeds 13,000 units. Between 2017 and 2019, over 50 new innovative start-ups active in biotechnology were registered. [2]
In the laboratories of the IRBM Science Park a team of Italian and American researchers has developed the Chad3Ebola-Zaire anti-ebola vaccine, a monovalent adenovirus capable of neutralizing the «Zaire» strain of the virus, conceived and produced by OKAIROS, a biotech company founded by Prof. Riccardo Cortese, with whom IRBM set up the Advent equal joint venture.
This section is empty. You can help by
adding to it. (January 2024) |
The research intensity of the biotech sector is significantly higher than that found for the Italian industry as a whole. [9]